Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)
Massimiliano Fabbiani(University of Siena), Simona Di Giambenedetto(Università Cattolica del Sacro Cuore), Roberto Cauda(Università Cattolica del Sacro Cuore), Andrea De Luca(Agostino Gemelli University Polyclinic), Nicoletta Ciccarelli(Università Cattolica del Sacro Cuore), Rita Murri(Agostino Gemelli University Polyclinic), Serena Fortuna(University of the Sacred Heart), Vincenzo Vullo(Sapienza University of Rome), Letizia Sidella(University of Siena), Francesca Paoletti(Sapienza University of Rome), A D’Avino(Università Cattolica del Sacro Cuore), Gabriella d’Ettorre(Policlinico Umberto I), Annalisa Mondi(Università Cattolica del Sacro Cuore), Manuela Colafigli(San Gallicano Hospital)
Cited by 29
Related Papers
Self-Reported Symptoms and Medication Side Effects Influence Adherence to Highly Active Antiretroviral Therapy in Persons With HIV Infection
|JAIDS Journal of Acquired Immune Deficiency Syndromes|2001|470
Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by<i>Klebsiella pneumoniae</i>Carbapenemase–producing<i>K. pneumoniae</i>
|Clinical Infectious Diseases|2018|351
Post-Traumatic Stress Symptoms in Healthcare Workers Dealing with the COVID-19 Pandemic: A Systematic Review
|International Journal of Environmental Research and Public Health|2021|272